Development Grants Accelerate Commercialization of Biomedical Technology


LIBHLIBCThe Long Island Bioscience Hub (LIBH), in cooperation with the Center for Biotechnology at Stony Brook University, awarded 13 technology development grants totaling $900,000 to researchers from Stony Brook University, Cold Spring Harbor Laboratory and Brookhaven National Laboratory. These grants represent a multi-tiered funding initiative aimed at contributing to a pipeline of commercially promising biomedical technology in the region.

The three funding initiatives include Feasibility, Proof of Concept and Commercialization awards. Feasibility awards are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications of an existing technology. Proof of Concept awards provide targeted, milestone-driven support for proof of concept research, development, testing and analysis of existing intellectual property. The final tier, Commercialization awards, provide targeted, milestone-driven support for a subset of projects with existing intellectual property in which additional investment will clearly advance the technology to a major value inflection point for commercialization.

The grants awarded in this first cycle support technologies developed across multiple disciplines including pharmacology, biomedical engineering, chemistry and microbiology; eight were Feasibility awards and five were Proof of Concept awards.

Feasibility Awards

  • Carol Carter, Professor, Department of Molecular Genetics and Microbiology, Stony Brook University, “Targeting Pathogenic Viral Infections with First-in-Class Viral Budding Inhibitors”
  • Michael Frohman, Professor and Chair, Department of Pharmacological Sciences, Stony Brook University, “Development of Small Molecule Inhibitors for PLD6 as Therapeutics for Triple Negative Breast Cancer”
  • Jingfang Ju, Associate Professor, Department of Pathology, Stony Brook University, “Novel miR-129 Based Therapeutics for Colon Cancer”
  • Dima Kozakov, Assistant Professor, Department of Applied Mathematics and Statistics, “Fast Hybrid Approach for Determination of Structure of Therapeutic Protein Complexes”
  • Gabriel Pagnotti, Post-doctoral Research Associate, Department of Biomedical Engineering, Stony Brook University, “Enhancement of Protein Yields Using Mechanical Signals: Augmenting Biotech Production to Reduce Drug Costs”
  • Yixian Qin, Professor, Department of Biomedical Engineering, Stony Brook University, “Non-invasive Acoustic Radiation Force Therapy for OA Induced Pain and Cartilage Regeneration”
  • Judy Wieber, Cold Spring Harbor Laboratory, “DNA Safe Deposit Box: A Smart Appliance for Secure Storage and Sharing of Biological Samples and Genomic Data in Clinical Laboratories”
  • Xinxin Yang, Postdoctoral Research Associate, Department of Chemistry, Stony Brook University, “LDL as Biomarker for Childhood Tuberculosis”

Proof of Concept Awards

  • Marcus Abboud, Associate Professor and Chair, Department of Prosthodontics, Stony Brook University, “A New Standard of Care for Implant Bed Preparation Utilizing an Innovative Drill Bit Technology”
  • Avraham Dilmanian, Brookhaven National Laboratory, “Orthovoltage X-Ray Minibeams: Brain Tumor Therapy with Tissue-sparing Incident Beams”
  • Amirhossein Goldan, Department of Radiology, Stony Brook University, “NEW‐HARP: A Highly Sensitive Avalanche Selenium Detector for Time‐of‐Flight Positron Emission Tomography”
  • Nicole Sampson, Professor and Chair, Department of Chemistry, Stony Brook University, “Azasteroids for Combination Anti-TB Therapy”
  • Eckard Wimmer, Distinguished Professor, Department of Molecular Genetics and Microbiology, “A Novel Glioblastoma Drug: Oncolytic Virus PV1-Mono-Cre”

“We are excited to see such a robust and diverse portfolio of early-stage technologies supported through the LIBH and NIH-REACH consortium,” said Clinton T. Rubin, chair of the Department of Biomedical Engineering at Stony Brook and director of the Center for Biotechnology. “We are hopeful that this investment by the federal and state government, as well as SBU, CSHL and BNL, will foster and accelerate the translation of these technologies from the bench to the bed side, and help attract further investment from the industrial and financial sectors.”

The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.

For more information please contact Diane Fabel, director of operations, Center for Biotechnology, at or (631) 632-8521.

Long Island Bioscience Hub
The Long Island Bioscience Hub, an NIH-designated Research, Evaluation, and Commercialization Hub, represents a partnership between the Center for Biotechnology, Stony Brook University, Cold Spring Harbor Laboratory and Brookhaven National Laboratory to commercialize biomedical innovations emerging from the partner institutions. In addition to the support provided by NIH and the partner institutions, the Long Island Bioscience Hub is supported by Empire State Development and The Research Foundation for SUNY. Together, the Center for Biotechnology and Long Island Bioscience Hub represent a significant opportunity to expand technology commercialization and company formation in the region and throughout New York State.

Center for Biotechnology at Stony Brook University
Established in 1983, the Center for Biotechnology (CFB) at Stony Brook is an Empire State Development Division of Science, Technology and Innovation (NYSTAR) Center for Advanced Technology. The CFB’s programs specifically target the development and commercialization of biomedical based technologies and critical components and staff of the LIBH is supported by the CFB.


About Author

Leave A Reply